Improved GAA activity in tregitope-treated pompe disease: preclinical studies (TECH1P.864)
Leslie P. Cousens(Providence College), Anne S. De Groot(Providence College), Dwight D. Koeberl(Duke Medical Center), Bill Martin(Providence College), Frances Terry(Providence College), Federico Mingozzi(Spark Therapeutics (United States))
Cited by 0
Related Papers
Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
|Science Translational Medicine|2013|346
Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy
|Journal of Clinical Investigation|2013|232
Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells
|Blood|2013|160
Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase
|Science Translational Medicine|2017|133